Tech Company Financing Transactions

SparingVision Funding Round

On 9/14/2022, SparingVision raised $75 million in Series B funding from JEITO, UPMC Enterprises and 4BIO Capital.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B

JEITO (Lead Investor) (Sabine Dandiguian)

UPMC Enterprises (Lead Investor) (Jeanne Cunicelli)

4BIO Capital


Foundation Fighting Blindness

Retinal Degeneration

Ysios Capital

Proceeds Purpose
Proceeds from the financing will be used to fund the first-in-human trials of the Company's two lead gene-independent assets, SPVN06 and SPVN20, as well as the development of genome editing assets through its collaboration with Intellia Therapeutics (NASDAQ: NTLA), a leading clinical-stage genome editing company. The financing extends SparingVision's cash runway to the second half of 2025.

Company Information

Company Status
Private & Independent
Mailing Address
5/7 avenue Percier CS40230
Paris, 75008
Email Address
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies.
SparingVision LinkedIn Company Profile
Social Media
SparingVision Company Twitter Account
Company News
SparingVision News
SparingVision on Facebook
SparingVision on YouTube

Management Team

Email & Social
Chief Executive Officer
Stanislas Piot
  Stanislas Piot LinkedIn Profile  Stanislas Piot Twitter Account  Stanislas Piot News  Stanislas Piot on Facebook
Chief Scientific Officer
Deniz Dalkara
  Deniz Dalkara LinkedIn Profile  Deniz Dalkara Twitter Account  Deniz Dalkara News  Deniz Dalkara on Facebook
Chief Technical Officer
Rajiv Gangurde
  Rajiv Gangurde LinkedIn Profile  Rajiv Gangurde Twitter Account  Rajiv Gangurde News  Rajiv Gangurde on Facebook
Thierry Léveillard
  Thierry Léveillard LinkedIn Profile  Thierry Léveillard Twitter Account  Thierry Léveillard News  Thierry Léveillard on Facebook



Browse more venture capital transactions:

Prev: 9/14/2022: Nile venture capital transaction
Next: 9/14/2022: NYSHEX venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary